Tagged with EG

India J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management in India; and the importance of actively championing diversity, equity, and inclusion (DEI) within the company, building a future-fit organization…

India Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a significant global presence. Siroya also outlines how Bal Pharma has evolved from its initial focus on the export market to…

Portugal Luis Abrantes explains how Generis, as one of the leading companies by volume in both the retail and hospital segments of the Portuguese pharma market, serves a huge number of patients in the country. Starting out in 2003 as a family-owned firm, it was then bought out by private equity…

Portugal Azevedos Group’s João Sotana outlines the firm’s diverse strategic pillars, including manufacturing for Portugal and international markets; its focus on sustainability and innovation; and how it plans to stay ahead of the pack in the competitive generics market, including via expansion into the US market with a focus on freeze-dried injectables.…

France After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its pipeline. With an FDA green light for its 2017-acquired Onivyde and an expected approval for its Genfit-partnered therapy this year,…

India Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal capabilities. With a ‘hypergrowth phase’ anticipated, Astellas will nevertheless need to continue to navigate India’s regulatory environment and engage in…

India Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines how Menarini positions itself as a leader in dermatology by treating dermo-cosmetics with the same rigour as pharmaceuticals and continuously…

Europe Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector. Building on his insights from last year, Westermann urges stakeholders to seize the opportunity caused by a delay in the…

USA US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is now targeting these companies and the potential impact of a proposed US Biosecure Act on US-China biotech ties.   Protecting…

Switzerland For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World Health Organisation (WHO), Swissmedic also saw a Good Manufacturing Practice (GMP) agreement between Switzerland and the US FDA come into…

India The State of Gujarat is one of India’s most culturally diverse, the birthplace of ‘Father of the Nation’ Mahatma Gandhi, and the only place in the world where Asiatic lions can be found in their natural habitat. It is also an economic powerhouse, with key Gujarati industries including dairy, cement,…

Portugal Alberto Navia-Osorio Pascual enthusiastically describes how Viatris has established itself as the leading pharmaceutical company in Portugal, leveraging the strengths of its integrated portfolios. The company has focused on brand recognition, customer engagement, and maintaining a strong relationship with healthcare professionals and pharmacists through extensive training initiatives. Navia-Osorio Pascual also…